Anti-Rejection Drug

Unlike simple non-cybernetic implants, like a hip replacement which can be made from hypoallergenic materials, there is a need for any cybernetic augmentation that will "feel" and can be moved by the mind to have a neuroprosthetic junction, junctions within the nervous system to act as the interface between body and machine. However, such connections cause glial tissue to build up around the junction, creating scar tissue on the nerve connections. The scarring eventually disrupts the integrity of the neuroprosthetic junction causing a rejection syndrome called Kauper-Engel Syndrome. A veriety of anti-rejection drugs exist to help combat this syndrome, which must be taken weekly, and are highly-regulated and patented by their various creators, making distribution difficult. Several different anti-rejection drugs exist on the market, each produced by a cybernetics corporation either directly or indirectly through subsidiaries. is a compound that prevents the buildup of glial nerve tissue around the junction.

Significance

The first publicly available anti-rejection drug, neurotyne, was developed by Swedish corporation Loftwise in 2013. The patent for this was sold to France-based Celerity Industries in 2016, though data regarding its creation was stolen in a data breach in 2017 and circulated among competing companies, specifically Praxis Heavy Industries. In 2018 Praxis Heavy Industries unveiled nervex, a next-generation anti-rejection drug with great similarities to neurotyne. Yamagato Industries produces nevrazene, its own proprietary anti-rejection drug. World cybernetics leader Crito Corporate also produces its own anti-rejection drug as well.

All anti-rejection drugs are available by prescription only and weekly doses are required to prevent the disruption of the junction. Although they are not produced with especially rare materials, their distribution is heavily controlled and can sell for extraordinary prices on the black market.

Anti-Rejection Drug

Currently in the keeping of:
Yamagato Industries, Crito Corporate, Praxis Heavy Industries, Celerity Industries

Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License